Accelerate Diagnostics Inc

Accelerate Diagnostics — Investor Presentation (June 2023)

20 slides from Accelerate Diagnostics's investor presentation, Jun 13, 2023

  1. Slide 1: Accelerate Diagnostics Investor Presentation

    ACCELERATE DIAGNOSTICS INVESTOR PRESNTATION Jack Phillips President & CEO Accelerate Diagnostics, Inc May 2023

  2. Slide 2: Confidentiality and disclaimer notice

    The information contained herein has been prepared by Accelerate Diagnostics, Inc. and its affiliates (the “Company”) and is highly confidential and proprietary information and may not be disclosed by the recipient to any other person or entity without the explicit written permission of the Company.

  3. Slide 3: Executive Summary

    Accelerate created the rapid microbiology testing market: first FDA approval, strong IP, notable customers, dozens of publications, and high clinical impact. New commercial partnership with Becton Dickinson driving near-term commercial momentum with Accelerate Pheno® and Accelerate Arc™ Next generat

  4. Slide 4: Corporate Strategic Priorities

    Grow Market Share Deliver Innovation Corporate Strategic Priorities Financial Strength Driven by Great People, working as One Team, aligned by a common Culture 4

  5. Slide 5: Target Market & Accelerate's Solutions

    Target Market & Accelerate’s Solutions 5

  6. Slide 6: Antimicrobial resistance & sepsis pose an escalating threat to healthcare

    Antimicrobial resistance & sepsis pose an on-going and escalating threat to healthcare (1) Management estimate based on an accumulation of publicly available data sources (2) Management estimate based on conglomeration of publicly available sources (3) P. Sallenriek, et. al. Comparison of MicroScan

  7. Slide 7: Accelerate's technology enables rapid & digitized microbiology

    Digital microbiology Fastest possible AST results Automated workflows Direct from sample capable Accelerate’s technology enables rapid & digitized microbiology Yesterday's microbiology Manual workflows Trained staff intensive Slow time to result 7

  8. Slide 8: Accelerate first to bring rapid digital testing to slow analog microbiology market

    Accelerate first to bring rapid digital testing to slow analog microbiology market CONVENTIONAL METHODS WORKFLOW (E.G. VITEK, PHOENIX, MICROSCAN) ACCELERATE PHENO & WAVE WORKFLOW 26-53 HRS EARLIER UP TO 8% mortality reduction 2 days less ABX usage 2 days length of stay reduction $1,000–3,100 per pat

  9. Slide 9: Large and evolving market creates risk to leaders & opportunity to disrupters

    Large and evolving market creates risk to leaders & substantial opportunity to disrupters US Ex-US Total Positive Blood – Rapid AST 2.3 5.8 8.1 Positive Blood/Myco – Rapid ID 3.0 7.6 10.6 Isolates – Rapid AST 38.5 86.8 125.3 Isolates – Rapid ID 59.7 134.4 194.1 Total: 103.5 234.5 338.0 (1) Approxima

  10. Slide 10: Accelerate Pheno System

    Accelerate Pheno® System Integrated ID/AST Test + AST Test 10

  11. Slide 11: Two available kits to meet varied customer workflows

    Two available kits to meet varied customer workflows Blood Culture Systems Bactec™ Virtuo® Positive Blood Culture Gram Stain Molecular Identification Biomerieux BioFire® Roche ePLEX® Diasorin Verigene® Rapid Susceptibility Accelerate PhenoTest® BC kit AST Configuration Rapid Identification & Suscept

  12. Slide 12: The financial benefit of running Pheno is proven

    The financial benefit of running Pheno is proven Length of Stay –3.0 days1 –2.6 days2 –2.0 days3 –1.8 days4 Time to Optimal Therapy –26.4 hours4 –22.1 hours2 –17.7 hours5 –17.3 hours1 Days on Therapy (DOT) –4.7 days2 –1.5 days7 –1.0 days4 Clinical Outcomes Data Reporting by Customers $3,100/patient

  13. Slide 13: Accelerate Arc Rapid MALDI Prep

    Accelerate Arc™ Rapid MALDI Prep 13

  14. Slide 14: Automated sample prep system creates an opportunity in the MALDI identification market

    Automated sample prep system creates an opportunity in the MALDI identification market ~1 hr Enables rapid MALDI Blood Culture Systems Bactec™ Virtuo® Positive Blood Culture Gram Stain Rapid Susceptibility Accelerate Pheno AST Test Rapid Identification & Susceptibility Result Reportable to LIS 2 Ste

  15. Slide 15: Wave Total Lab AST Solution

    Wave™ Total Lab AST Solution 15

  16. Slide 16: Wave: Advancing rapid susceptibility testing for positive blood culture and isolates

    Wave: Advancing rapid susceptibility testing for positive blood culture and isolates with a decade of innovation Access to 10X more testing volume with isolated colony assays 90% less costly than Pheno Positive Blood Culture (PBC) consumable, highly profitable PBC and Isolate Assays Scalable system

  17. Slide 17: Wave unleashes the power of proprietary holographic imaging

    Wave unleashes the power of proprietary holographic imaging Wave Delivers • Faster single-cell analysis • Improved noise reduction, eliminate complexity without compromising signal • Enhanced accuracy for complex cases • Rich data stream which enables continued learning, and applications beyond micr

  18. Slide 18: The Opportunity: Wave expands available market by 15x

    The Opportunity: Wave expands available market by 15x Pheno ID/AST Segment Pheno AST Segment Wave Arc Isolates Rapid ID Isolates Rapid AST Positive Blood Culture Rapid AST PBC/Myco Rapid ID Expansion of Addressable Market with Wave: • Next generation Antimicrobial Susceptibility Testing (AST) platfo

  19. Slide 19: Projections

    Projections 19

  20. Slide 20: Long-Term Financial Model

    20 Long-Term Financial Model 1,2,3,4 Long-Term Financial Forecast ($ millions) (1) These are goals reflective of the midpoint of management assessment of the company's opportunity - this does not reflect formal financial guidance and should not be relied on as such. See “Cautionary Note Regarding Pr

Accelerate Diagnostics — Investor Presentation (June 2023) on 6ix